Study Summary
This trialtests whether adding almond therapy to esketamine can help people better than just esketamine alone.
- Treatment-Resistant Depression
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: Screening, Day 2, 5, 9, 12,16, ,19, 23, 26 and 28
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
0 Treatment Group
6 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 64 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this research initiative currently looking for participants?
"Affirmative. Clinicaltrials.gov shows that this research, first posted on October 13th 2022, is presently looking for enrollees. 102 individuals must enroll at one medical centre to complete the trial." - Anonymous Online Contributor
What is the magnitude of participants in this clinical experiment?
"Affirmative. Entries on clinicaltrials.gov conclusively demonstrate that this investigation is currently seeking patients, having been initiated on October 13th 2022 and amended most recently on November 9th 2022. 102 individuals are required from a solitary medical centre for the trial to be completed successfully." - Anonymous Online Contributor
Who is eligible to participate in this research experiment?
"The prerequisites for this trial necessitate that applicants have a diagnosis of unipolar depression and be aged between 18 to 64. All told, 102 participants are required in order to complete the study." - Anonymous Online Contributor
Are the eligibility requirements of this trial inclusive to those aged 70 and above?
"The inclusion criteria for this trial necessitate that participants are aged 18 or more, yet less than 64 years of age." - Anonymous Online Contributor
How efficacious is this procedure for those under its care?
"Due to the Phase 2 status of this trial, there is partial evidence that suggests safety but no data available yet for efficacy. Therefore, our team rated the safety as a score of 2 on a 1-3 scale." - Anonymous Online Contributor